Wilex AG Stock Deutsche Boerse AG
Equities
DE0006614720
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
Mar. 27 | Heidelberg Pharma Wins US FDA Orphan Drug Designation for Multiple Myeloma Treatment | MT |
Mar. 25 | Transcript : Heidelberg Pharma AG, 2023 Earnings Call, Mar 25, 2024 |
Sales 2024 * | 11.5M 12.25M | Sales 2025 * | 15M 15.98M | Capitalization | 140M 149M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 12.2 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 9.32 x |
P/E ratio 2024 * |
-10
x | P/E ratio 2025 * |
-23.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 16.94% |
Latest transcript on Wilex AG
Managers | Title | Age | Since |
---|---|---|---|
Andreas Pahl
CEO | Chief Executive Officer | - | 11-12-31 |
Walter Miller
DFI | Director of Finance/CFO | - | 23-04-30 |
András Strassz
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 60 | 05-04-28 | |
Georg F. Baur
BRD | Director/Board Member | 74 | 00-12-13 |
Birgit Kudlek
BRD | Director/Board Member | 57 | 12-05-24 |
1st Jan change | Capi. | |
---|---|---|
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |